Close Menu

NEW YORK – Epigenetic markers can distinguish between individuals with type 2 diabetes who respond to metformin treatment and those who do not, a new study has found. 

Metformin is commonly prescribed to individuals with type 2 diabetes, but about 30 percent of patients don't respond to the drug and between 20 percent and 30 percent experience side effects that can be intolerable.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

According to the Washington Post, the Biden Administration is set to make changes to federal restrictions on fetal tissue research.

NPR reports that researchers have developed chimeric embryos as part of work toward growing human organs in animals for organ transplants.

In Science this week: approach to isolated trace DNA from archaic humans from sediments, and more.

Texas Monthly looks into the DNA Zoo being collected by Baylor College of Medicine researchers.

Sponsored by

This webinar will discuss a study that sought to identify early biomarkers for cancer by analyzing pre-diagnosis samples from seemingly healthy individuals who were later diagnosed with cancer.